Program Description
Psoriasis affects approximately 8 million individuals in the United States and 125 million individuals worldwide, making it the most common immune-mediated inflammatory disease in North America and Europe. Psoriasis is characterized by recurrent exacerbations and remissions of thickened, erythematous, and scaling plaques, with patients often facing a considerable impact on their quality of life due to burdens such as social stigmatization and physical disability. However, nontreatment and undertreatment of psoriasis continue to be significant problems in the United States regardless of treatment accessibility. Pharmacists specifically have an opportunity to exert a positive effect on patient outcomes via patient education and monitoring to optimize outcomes. This activity will review recent data on new treatment options as well as best practices in applying the clinical data to improve patient outcomes, reduce complications, and lower health care costs for both patients and the health care system.
Target audience: Managed care pharmacists, specialty pharmacists
Type of activity: Application
Release date: May 18, 2023
Expiration date: May 18, 2024
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology, risk factors, and clinical manifestations of plaque psoriasis and its substantial burden and impact on patient quality of life
- Determine the current limitations with traditional therapies and the evolving role of the newest biologic agents that address disease pathogenesis
- Identify the role of the pharmacist in the management of plaque psoriasis including making clinical recommendations, facilitating access to care, and educating patients to optimize outcomes
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
